ATARA BIOTHERAPEUTICS, INC. (ATRA) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 6.85M USD | Liabilities, Current |
| Cash and equivalents | 3.22M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Available-for-sale Securities, Current |
| Customer receivables | 318.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $6.85M | $3.22M | (m) | $318.00K | (m) | (m) |
| 2026-03-31 | (m) | $5.64M | $8.36M | (m) | $0.00 | (m) | (m) |
| 2025-12-31 | (m) | $14.92M | $8.48M | (m) | $1.25M | $0.00 | (m) |
| 2025-09-30 | (m) | $18.06M | $5.74M | (m) | $1.91M | $0.00 | (m) |
| 2025-06-30 | (m) | $14.56M | $16.90M | (m) | $0.00 | $0.00 | (m) |
| 2025-03-31 | (m) | $47.89M | $13.84M | (m) | $8.88M | $0.00 | (m) |
| 2024-12-31 | (m) | $134.57M | $25.03M | (m) | $1.48M | $10.65M | (m) |
| 2024-09-30 | (m) | $155.98M | $46.45M | (m) | $1.33M | $13.98M | (m) |
| 2024-06-30 | (m) | $148.27M | $31.31M | (m) | $2.42M | $18.75M | (m) |
| 2024-03-31 | (m) | $180.69M | $35.09M | (m) | $35.83M | $16.08M | (m) |
| 2023-12-31 | (m) | $142.23M | $25.84M | (m) | $34.11M | $9.71M | (m) |
| 2023-09-30 | (m) | $79.09M | $64.79M | (m) | $163.00K | $6.59M | (m) |
| 2023-06-30 | (m) | $74.55M | $45.90M | (m) | $507.00K | $7.86M | (m) |
| 2023-03-31 | (m) | $67.88M | $48.74M | (m) | $397.00K | $5.34M | (m) |
| 2022-12-31 | (m) | $78.92M | $92.94M | (m) | $40.22M | $1.59M | (m) |
| 2022-09-30 | (m) | $72.24M | $65.11M | (m) | $249.00K | (m) | (m) |
| 2022-06-30 | (m) | $65.69M | $70.69M | (m) | $637.00K | (m) | (m) |
| 2022-03-31 | (m) | $101.56M | $101.67M | (m) | $668.00K | (m) | (m) |
| 2021-12-31 | (m) | $105.79M | $106.08M | (m) | $986.00K | (m) | (m) |
| 2021-09-30 | (m) | $86.15M | $113.21M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $88.83M | $123.86M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $84.19M | $151.10M | (m) | $9.61M | (m) | (m) |
| 2020-12-31 | (m) | $82.90M | $200.40M | (m) | $1.25M | (m) | (m) |
| 2020-09-30 | (m) | $36.05M | $62.62M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $31.68M | $74.51M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $31.52M | $70.20M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $36.74M | $74.32M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $30.71M | $94.43M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $25.80M | $59.16M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $25.18M | $56.17M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $39.98M | $60.70M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $27.00M | $66.03M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $27.23M | $103.20M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $21.05M | $90.50M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $27.65M | $79.22M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $16.52M | $60.49M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $11.48M | $64.24M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $7.80M | $62.43M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $9.68M | $47.97M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $13.69M | $46.01M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $10.01M | $26.36M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $8.86M | $22.06M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $9.71M | $23.75M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $6.45M | $54.47M | $279.80M | (m) | (m) | (m) |
| 2015-06-30 | (m) | $11.64M | $26.19M | $128.84M | (m) | (m) | (m) |
| 2015-03-31 | (m) | $3.51M | $71.33M | $95.37M | (m) | (m) | (m) |
| 2014-12-31 | (m) | $2.72M | $21.90M | $82.22M | (m) | (m) | (m) |
| 2014-09-30 | (m) | $2.41M | $25.70M | $26.00M | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $31.78M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $39.75M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $1.52M | $51.62M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | $15.69M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $4.21M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |